midazolam has been researched along with sirolimus in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beck, WT; Schuetz, EG; Schuetz, JD | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Benet, LZ; Christians, U; Cummins, CL; Jacobsen, W | 1 |
| Bouillaud, E; Cheung, W; Delaney, R; Jappe, A; Urva, S | 1 |
| Agrawal, N; Breidinger, S; Lush, R; McCrea, J; Narasimhan, N; Orford, K; Palcza, J; Panebianco, D; Papadopoulos, KP; Patnaik, A; Sandhu, P; Stroh, M; Talaty, J; Tolcher, A; Trucksis, M; Wagner, JA | 1 |
| Depaulis, A; Laharie, AM; Nitta, N; Nozaki, K; Shima, A; Suzuki, F | 1 |
1 review(s) available for midazolam and sirolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for midazolam and sirolimus
| Article | Year |
|---|---|
A phase I study evaluating the effect of everolimus on the pharmacokinetics of midazolam in healthy subjects.
Topics: Adult; Anti-Anxiety Agents; Drug Interactions; Everolimus; Humans; Hypnotics and Sedatives; Immunosuppressive Agents; Male; Midazolam; Middle Aged; Sirolimus; Young Adult | 2013 |
Lack of meaningful effect of ridaforolimus on the pharmacokinetics of midazolam in cancer patients: model prediction and clinical confirmation.
Topics: Aged; Anti-Anxiety Agents; Antineoplastic Agents; Area Under Curve; Drug Interactions; Female; Half-Life; Humans; Male; Midazolam; Middle Aged; Models, Biological; Sirolimus | 2014 |
5 other study(ies) available for midazolam and sirolimus
| Article | Year |
|---|---|
Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.
Topics: Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Blotting, Northern; Cell Line; Clotrimazole; Colonic Neoplasms; Cytochrome P-450 CYP2E1; Cytochrome P-450 Enzyme System; Dexamethasone; DNA Primers; Doxorubicin; Gene Expression Regulation, Neoplastic; Humans; Midazolam; Mixed Function Oxygenases; Molecular Sequence Data; Multigene Family; Phenobarbital; Phenytoin; Polymerase Chain Reaction; Rifampin; Tumor Cells, Cultured; Verapamil | 1996 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam.
Topics: Absorption; Animals; Biological Transport; Caco-2 Cells; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dogs; Humans; Immunosuppressive Agents; Midazolam; Sirolimus; Transfection | 2004 |
Activation of mTOR signaling pathway is secondary to neuronal excitability in a mouse model of mesio-temporal lobe epilepsy.
Topics: Animals; Astrocytes; Brain-Derived Neurotrophic Factor; Central Nervous System Agents; Disease Models, Animal; Epilepsy, Temporal Lobe; Gliosis; Hippocampus; Kainic Acid; Male; Mice, Inbred C57BL; Midazolam; Neural Inhibition; Neurons; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2015 |